Skip to main content
Top

Endocrine Pathology

Issue 4/2012

Content (9 Articles)

Adequacy of Pathology Reports of Specimens from Patients with Differentiated Thyroid Cancer

Ma Luisa Isidro, Gloria Lugo, Olga Fidalgo, Sara García-Arias

Biomarkers of Parathyroid Carcinoma

Boban M. Erovic, Luke Harris, Mina Jamali, David P. Goldstein, Jonathan C. Irish, Sylvia L. Asa, Ozgur Mete

Prognostic and Predictive Markers in Medullary Thyroid Carcinoma

Boban M. Erovic, Dae Kim, Clarissa Cassol, David P. Goldstein, Jonathan C. Irish, Sylvia L. Asa, Ozgur Mete

Expression of Stromal Cell-Derived Factor 1 and CXCR7 in Papillary Thyroid Carcinoma

Zhen Liu, Da-Xin Sun, Xu-Yong Teng, Wei-Xue Xu, Xiang-Peng Meng, Bao-Sheng Wang

Villous Papillary Thyroid Carcinoma: a Variant Associated with Marfan Syndrome

Daniel A. Winer, Shawn Winer, Lorne Rotstein, Sylvia L. Asa, Ozgur Mete

Giant Amyloid Goiter in Crohn’s Disease

Beatriz Febrero, Antonio Ríos, Jose Manuel Rodríguez, Belén Ferri, Luis Polo, Pascual Parrilla

Pituitary Metastasis Presenting as Ischemic Pituitary Apoplexy Following Heparin-induced Thrombocytopenia

Ivan Kruljac, Vatroslav Čerina, Hrvoje Ivan Pećina, Leo Pažanin, Tomas Matić, Velimir Božikov, Milan Vrkljan

Acute Lymphoblastic Leukaemia (ALL) with Infiltration of the Thyroid: a Cytological Diagnosis

Rajeev Sen, Sumiti Gupta, Ashima Batra, Meenu Gill, Veena Gupta, Nisha Marwah

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine